326 related articles for article (PubMed ID: 36154607)
1. Advances on Epigenetic Drugs for Pediatric Brain Tumors.
Skouras P; Markouli M; Strepkos D; Piperi C
Curr Neuropharmacol; 2023; 21(7):1519-1535. PubMed ID: 36154607
[TBL] [Abstract][Full Text] [Related]
2. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
3. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
[TBL] [Abstract][Full Text] [Related]
4. Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy.
Cacciotti C; Fleming A; Ramaswamy V
J Pathol; 2020 Jul; 251(3):249-261. PubMed ID: 32391583
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms and therapeutic targets in pediatric brain tumors.
Liu KW; Pajtler KW; Worst BC; Pfister SM; Wechsler-Reya RJ
Sci Signal; 2017 Mar; 10(470):. PubMed ID: 28292958
[TBL] [Abstract][Full Text] [Related]
6. Developmental origins and oncogenic pathways in malignant brain tumors.
Lu QR; Qian L; Zhou X
Wiley Interdiscip Rev Dev Biol; 2019 Jul; 8(4):e342. PubMed ID: 30945456
[TBL] [Abstract][Full Text] [Related]
7. Emerging Epigenetic Therapies for Brain Tumors.
Kukreja L; Li CJ; Ezhilan S; Iyer VR; Kuo JS
Neuromolecular Med; 2022 Mar; 24(1):41-49. PubMed ID: 34677796
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic-Based Therapy-A Prospective Chance for Medulloblastoma Patients' Recovery.
Strejczek A; Woszczyk D; Urbaniak H; Różańska M; Robak M; Matuszewska Z; Barciszewska AM
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066495
[TBL] [Abstract][Full Text] [Related]
9. Neuro-oncology: Genetic variation in pediatric and adult brain tumors.
Brandes AA; Franceschi E
Nat Rev Neurol; 2010 Dec; 6(12):653-4. PubMed ID: 21131914
[TBL] [Abstract][Full Text] [Related]
10. Review of the genomic landscape of common pediatric CNS tumors and how data sharing will continue to shape this landscape in the future.
Kaneva K; Goldman S
Mol Biol Rep; 2021 Nov; 48(11):7537-7544. PubMed ID: 34643931
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic regulation in medulloblastoma.
Yi J; Wu J
Mol Cell Neurosci; 2018 Mar; 87():65-76. PubMed ID: 29269116
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges.
Pollack IF
J Neurosurg Pediatr; 2011 Aug; 8(2):135-48. PubMed ID: 21806354
[TBL] [Abstract][Full Text] [Related]
13. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.
de Bont JM; Packer RJ; Michiels EM; den Boer ML; Pieters R
Neuro Oncol; 2008 Dec; 10(6):1040-60. PubMed ID: 18676356
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated
Ramsawhook A; Lewis L; Coyle B; Ruzov A
Clin Epigenetics; 2017; 9():18. PubMed ID: 28228863
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic events in medulloblastoma development.
Lindsey JC; Anderton JA; Lusher ME; Clifford SC
Neurosurg Focus; 2005 Nov; 19(5):E10. PubMed ID: 16398460
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics and survivorship in pediatric brain tumor patients.
Bhattacharya D; Pomeroy SL; Pomeranz Krummel DA; Sengupta S
J Neurooncol; 2020 Oct; 150(1):77-83. PubMed ID: 32451770
[TBL] [Abstract][Full Text] [Related]
17. Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics.
Batora NV; Sturm D; Jones DT; Kool M; Pfister SM; Northcott PA
Neuroscience; 2014 Apr; 264():171-85. PubMed ID: 23876321
[TBL] [Abstract][Full Text] [Related]
18. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
19. Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics.
Sokolov D; Sharda N; Banerjee A; Denisenko K; Basalious EB; Shukla H; Waddell J; Hamdy NM; Banerjee A
Curr Pharm Des; 2024; 30(1):31-47. PubMed ID: 38151840
[TBL] [Abstract][Full Text] [Related]
20. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
